Modality
Radioligand
MOA
SOS1i
Target
CD123
Pathway
Checkpoint
DMD
Development Pipeline
Preclinical
~May 2017
→ ~Aug 2018
Phase 1
Nov 2018
→ Jan 2026
Phase 1Current
NCT08154324
2,431 pts·DMD
2022-09→TBD·Terminated
NCT04706421
342 pts·DMD
2018-11→2026-01·Active
2,773 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-242mo agoInterim· DMD
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P1
Active
P1
Termina…
Catalysts
Interim
2026-01-24 · 2mo ago
DMD
ActiveTerminated|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| HAL-1232 | Halozyme | Approved | C5 |